Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease

Chronic graft-versus-host disease (cGvHD) remains a major barrier to a successful hematopoietic stem cell transplantation (HSCT) associated with lower quality of life (QOL) and significant morbidity and mortality.1 Corticosteroids are widely accepted as first-line therapy and most often recommended by expert consensus groups.2 Unfortunately, a significant percentage of cGvHD patients do not improve with steroids, and there is no widely agreed-upon second-line agent to treat these patients.3

Source: Biology of Blood and Marrow Transplantation - September 7, 2018 Category: Hematology Authors: Badri Modi, Michael Hernandez-Henderson, Dongyun Yang, Jeremy Klein, Sanjeet Dadwal, Erin Kopp, Karen Huelsman, Sally Mokhtari, Haris Ali, Monzr M. Al Malki, Ricardo Spielberger, Amandeep Salhotra, Pablo Parker, Stephen Forman, Ryotaro Nakamura Source Type: research